Answers are grounded in this paper and cite their sources.
Correction to: Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen Arzneimittelforschung 2012; 62(09): 401-409 DOI: 10.1055/s-0032-1321831 Erratum Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen B. Bittner, W. F. Richter, F. Hourcade-Potelleret, C. McIntyre, F. Herting, M. L. Zepeda, J. Schmidt Arzneimittelforschung 2012; 62: 401–409 DOI: 10.1055/s-0032-1321831 The references referring to other sections like “Section 6.4“ are no longer valid as the new formatting removed the numbers for the different paragraphs in the article.
No takes yet. Share an insight, caveat, or question.
Bittner et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: